Zhejiang Hisoar Pharmaceutical Co., Ltd.

Zhejiang Hisoar Pharmaceutical Co., Ltd. (Hereinafter referred to as “Hisoar Pharma”, Stock code#002099), located in Taizhou, Zhejiang. It is a IPO listed company holding by DanKong Group, which mainly manufacture APIs, Formulations, Fine chemicals, Dyestuffs and Dyetuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry, a key high-tech company in the State Torch Plan, one of the first integrity demonstration companies in Zhejiang Province, and an excellent self-support export manufacturing company in Zhejiang Province. The main product categories are antibiotics, cardiovascular, hypoglycemic and others, fine chemicals, formulations, dyes and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in leading position worldwide. The company pays great attention on EHS and GMP system establishment, and having dozens of products registered with US FDA, CEP (COS) certificate granted, and got the GMP certificates from Japanese PMDA and Chinese FDA. Dye products are exported to more than 30 countries covering the regions of Europe, America and Asia, in which Reactive blue 19 KN-R, as a leading product, takes up more than 60% of the global market share, keeping a leading position in the industry based on its production capacity, technical quality and product application. Establishment of long-term cooperation with the global well-known pharmaceutical and dye companies is our development principle, the cooperated partners such as Pfizer, Boehringer Ingelheim, BASF, Sanofi, Novartis, Janssen, Sumitomo Chemical, DSTAR, Huntsman and son on.